---
title: An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
nct_id: NCT00721981
overall_status: TERMINATED
sponsor: AstraZeneca
study_type: OBSERVATIONAL
primary_condition: Lung Cancer
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00721981.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00721981"
ct_last_update_post_date: 2010-12-10
last_seen_at: "2026-05-12T06:30:12.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy

**Official Title:** A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment

**NCT ID:** [NCT00721981](https://clinicaltrials.gov/study/NCT00721981)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Low Recruitment
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 120
- **Lead Sponsor:** AstraZeneca
- **Conditions:** Lung Cancer, Non-small Cell Lung Cancer
- **Start Date:** 2009-04
- **Completion Date:** 2009-10
- **CT.gov Last Update:** 2010-12-10

## Brief Summary

The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours
* Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment)
* Patients who are in transition from first to second line treatment
* Patients who signed an informed consent

Exclusion Criteria:

* Chemotherapy naïve patients
* Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy)
* Patients who ever had chemotherapy for an indication other than NSCLC
```

## Arms

- **1** — Regular treatment for non-small cell lung cancer (NSCLC)

## Primary Outcomes

- **To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment** _(time frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy)_

## Secondary Outcomes

- **current medical practice treatment objectives and modalities side effects** _(time frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy)_
- **socioeconomic status and demographics patients' perception of their health status and treatment patient values and patient preferences** _(time frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy)_

## Locations (8)

- Research Site, Berlin, Germany
- Research Site, Essen, Germany
- Research Site, Heidelberg, Germany
- Research Site, Hemer, Germany
- Research Site, Karlsruhe, Germany
- Research Site, Löwenstein, Germany
- Research Site, München, Germany
- Research Site, Trier, Germany

## Recent Field Changes (last 30 days)

- `locations.research site|münchen||germany` — added _(2026-05-12)_
- `locations.research site|trier||germany` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.research site|berlin||germany` — added _(2026-05-12)_
- `locations.research site|essen||germany` — added _(2026-05-12)_
- `locations.research site|heidelberg||germany` — added _(2026-05-12)_
- `locations.research site|hemer||germany` — added _(2026-05-12)_
- `locations.research site|karlsruhe||germany` — added _(2026-05-12)_
- `locations.research site|löwenstein||germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00721981.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00721981*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*